查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年亚太地区传染病治疗市场预测 - 区域分析 - 按药物类别、适应症、给药途径和配销通路
市场调查报告书
商品编码
1562250

2030 年亚太地区传染病治疗市场预测 - 区域分析 - 按药物类别、适应症、给药途径和配销通路

Asia Pacific Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 101 Pages | 订单完成后即时交付

价格

2022年亚太传染病治疗市值为259.0461亿美元，预计2030年将达到374.1507亿美元；预计2022年至2030年复合年增长率为4.7%。

发展中国家不断增长的机会推动亚太传染病治疗市场

传染病发病率的不断上升预计将增加发展中国家传染病治疗药物的销售。由于资料需求适度减少和严格的法规，亚太地区已成为一个适应性强且有利于商业的中心。此外，新兴国家对健康研究和生命科学的高投入对于促进发展中国家的最新技术发挥关键作用，这反过来又支持了传染病诊断和治疗的倾向。例如，联合国爱滋病规划署呼吁到2025年投资290亿美元，以满足中低收入国家应对爱滋病的需求。因此，印度和韩国新兴传染病治疗市场的重要传染病治疗产品製造商预计未来将见证利润丰厚的机会。这是由于肝炎、HAI、HIV 和流感等传染病的高流行所致；大量患者；人口可支配所得增加；改善医疗保健基础设施；这些国家不断成长的医疗旅游业。

亚太地区传染病治疗市场概况

亚太传染病治疗市场细分为中国、印度、日本、韩国、澳洲和亚太其他地区。预计亚太地区在预测期内复合年增长率最快。由于全球医疗保健支出增加、慢性病和传染病发病率增加以及老年人口基数不断增加，预计该地区的市场将成长。中国常见流感、B型肝炎、感染性腹泻等传染病，印度常见伤寒、疟疾、黄疸、结核病、爱滋病等。流感、B型肝炎、感染性腹泻是我国常见的三大传染病。根据Frontiers Public Health报道，2021年冬季流感高峰期恰逢该国爆发COVID-19。高。考虑到该国传染病发病率不断上升，世界银行执行董事会批准为新兴传染病预防、准备和应对计画提供3亿美元贷款。这将有助于降低人畜共患病和其他新出现的健康威胁的风险。因此，传染病发病率的上升以及为控制这些疾病而采取的措施预计将在未来几年推动中国传染病治疗市场的发展。

亚太地区传染病治疗市场收入及 2030 年预测（百万美元）

亚太地区传染病治疗市场区隔

亚太传染病治疗市场按药物类别、适应症、给药途径、配销通路和国家分类。

依药物类别，亚太传染病治疗市场分为抗病毒、抗菌、抗真菌等。 2022 年，抗病毒药物领域占据最大的市场份额。

从适应症来看，亚太传染病治疗市场分为爱滋病毒、肝炎、结核病、流感、HPV等。 2022 年，HIV 占据最大的市场份额。

根据给药途径，亚太传染病治疗市场分为口服、肠胃外、外用等。 2022 年，口腔细分市场占据最大的市场份额。

从配销通路来看，亚太传染病治疗市场分为医院药局、零售药局等。 2022年，医院药局占最大的市场份额。

依国家/地区划分，亚太传染病治疗市场分为中国、日本、印度、澳洲、韩国和亚太其他地区。 2022年，中国在亚太传染病治疗市场份额中占据主导地位。

艾伯维公司(AbbVie Inc)、安斯泰来製药公司(Astellas Pharma Inc)、拜耳公司(Bayer AG)、霍夫曼-拉罗氏有限公司(F. Hoffmann-La Roche Ltd)、吉利德科学公司(Gilead Sciences Inc)、葛兰素史克公司(GSK Plc)、默克公司(Merck & Co Inc)、辉瑞公司(Pfizer Inc) 和盐野义公司(Shionogi & Co Ltd) 是亚太地区传染病领域的一些领先公司疾病治疗市场。

目录

第 1 章：简介

第 2 章：执行摘要

  • 主要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：亚太地区传染病治疗市场 - 主要市场动态

  • 亚太传染病治疗市场 - 主要市场动态
  • 市场驱动因素
    • 传染病病率上升
    • 越来越关注传染病治疗的经费与研发
  • 市场限制
    • 抗感染药物抗药性的出现及相关副作用
  • 市场机会
    • 发展中国家不断成长的机会
    • 抗生素抗药性威胁不断升级
  • 未来趋势
    • 产品批准和发布数量不断增加
  • 驱动因素和限制的影响：

第 5 章：传染病治疗市场 - 亚太市场分析

  • 2022-2030 年亚太地区传染病治疗市场收入

第 6 章：亚太地区传染病治疗市场分析 - 按药物类别

  • 概述
  • 抗病毒剂
  • 抗菌
  • 抗真菌
  • 其他的

第 7 章：亚太地区传染病治疗市场分析 - 按适应症

  • 概述
  • 爱滋病
  • 肝炎
  • 结核
  • 流感
  • HPV病毒
  • 其他的

第 8 章：亚太地区传染病治疗市场分析 - 按给药途径

  • 概述
  • 口服
  • 注射用
  • 专题
  • 其他的

第 9 章：亚太地区传染病治疗市场分析 - 按配销通路

  • 概述
  • 医院药房
  • 零售药局
  • 其他的

第 10 章：亚太地区传染病治疗市场 - 国家分析

  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区

第 11 章：传染病治疗市场-产业格局

  • 概述
  • 传染病治疗市场的成长策略
  • 无机成长策略
    • 概述
  • 有机成长策略
    • 概述

第 12 章：公司简介

  • Pfizer Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Shionogi & Co Ltd
  • Bayer AG
  • GSK Plc
  • AbbVie Inc
  • Merck & Co Inc
  • Astellas Pharma Inc

第 13 章：附录

Product Code: BMIRE00030366

The Asia Pacific infectious disease therapeutics market was valued at US$ 25,904.61 million in 2022 and is expected to reach US$ 37,415.07 million by 2030; it is estimated to register a CAGR of 4.7% from 2022 to 2030.

Growing Opportunities in Developing Nations Boost Asia Pacific Infectious Disease Therapeutics Market

The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. Asia Pacific has become an adaptable and business-friendly hub due to moderately fewer data requirements and stringent regulations. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is calling for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in the AIDS response. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in India and South Korea, are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries.

Asia Pacific Infectious Disease Therapeutics Market Overview

The Asia Pacific infectious disease therapeutics market is sub-segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR during the forecast period. The market in the region is expected to grow owing to rising global healthcare expenditure, increasing incidence of chronic and infectious diseases, and a growing geriatric population base. The infectious disease such as influenza, hepatitis B, and infectious diarrhea are common in China and typhoid, malaria, jaundice, tuberculosis, and AIDS in India. Influenza, hepatitis B, and infectious diarrhea are the three common infectious diseases in China. As stated by Frontiers Public Health, the winter peak of influenza coincided with the outbreak of COVID-19 in the country in 2021. According to the World Bank Country Director of China 2020, the country is at a high risk of infectious diseases due to its growing population, wildlife abundance, habitat fragmentation, and high livestock production levels. Considering the country's growing incidence of infectious diseases, the World Bank's Board of Executive Directors approved a US$ 300 million loan for the Emerging Infectious Diseases Prevention, Preparedness and Response Project. This will help it reduce the risk of zoonotic and other emerging health threats. Thus, the rising incidence of infectious diseases and measures taken to control these diseases are expected to boost the China infectious disease therapeutics market in the coming years.

Asia Pacific Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Infectious Disease Therapeutics Market Segmentation

The Asia Pacific infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the Asia Pacific infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the Asia Pacific infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the Asia Pacific infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the Asia Pacific infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the Asia Pacific infectious disease therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Asia Pacific infectious disease therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics

  • 4.1 Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Infectious Disease
    • 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
  • 4.4 Market Opportunities
    • 4.4.1 Growing Opportunities in Developing Nations
    • 4.4.2 Escalating Threat of Antibiotic Resistance
  • 4.5 Future Trends
    • 4.5.1 Rising Number of Product Approvals and Launches
  • 4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - Asia Pacific Market Analysis

  • 5.1 Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Drug Class

  • 6.1 Overview
  • 6.2 Anti-Viral
    • 6.2.1 Overview
    • 6.2.2 Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Anti-bacterial
    • 6.3.1 Overview
    • 6.3.2 Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Anti-fungal
    • 6.4.1 Overview
    • 6.4.2 Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Indication

  • 7.1 Overview
  • 7.2 HIV
    • 7.2.1 Overview
    • 7.2.2 HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Hepatitis
    • 7.3.1 Overview
    • 7.3.2 Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Tuberculosis
    • 7.4.1 Overview
    • 7.4.2 Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Influenza
    • 7.5.1 Overview
    • 7.5.2 Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 HPV
    • 7.6.1 Overview
    • 7.6.2 HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Topical
    • 8.4.1 Overview
    • 8.4.2 Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Retail Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Infectious Disease Therapeutics Market - Country Analysis

  • 10.1 Asia Pacific Infectious Disease Therapeutics Market Overview
    • 10.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
      • 10.1.1.3 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 China: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.3.2 China: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.3.3 China: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.3.4 China: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.4 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
      • 10.1.1.5 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 Japan: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.5.2 Japan: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.5.3 Japan: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.5.4 Japan: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.6 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
      • 10.1.1.7 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.7.1 India: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.7.2 India: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.7.3 India: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
        • 10.1.1.7.4 India: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.8 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.8.1 Overview
      • 10.1.1.9 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.9.1 Australia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.9.2 Australia: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.9.3 Australia: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
        • 10.1.1.9.4 Australia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.10 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.10.1 Overview
      • 10.1.1.11 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.11.1 South Korea: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.11.2 South Korea: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.11.3 South Korea: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.11.4 South Korea: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.12 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.12.1 Overview
      • 10.1.1.13 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.13.1 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.13.2 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.13.3 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.13.4 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Infectious Disease Therapeutics Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Pfizer Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Gilead Sciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 F. Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Shionogi & Co Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Bayer AG
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 GSK Plc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AbbVie Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Merck & Co Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Astellas Pharma Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners

List Of Tables

  • Table 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation
  • Table 2. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
  • Table 3. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
  • Table 4. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 5. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 6. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 7. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 8. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 9. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 10. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 11. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 12. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 13. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 14. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 15. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 16. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 17. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
  • Table 18. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 19. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 20. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 21. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
  • Table 22. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 23. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 24. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 25. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 26. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 27. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 28. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 29. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 30. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
  • Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List Of Figures

  • Figure 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
  • Figure 4. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
  • Figure 5. Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
  • Figure 10. HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
  • Figure 17. Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Asia Pacific Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 31. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 32. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market